Urocortin
Urocortin is a 40-aa CRF-family peptide that activates both CRF-R1 and CRF-R2 receptors. It modulates stress responses, anxiety, appetite suppression, cardiac function (positive inotropy via CRF-R2), and immune regulation.
Community Rating
No ratings yet
Compound Profile
Urocortin
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Urocortin is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Activates CRF-R2 receptors more potently than CRF (CRH) itself — mediates stress-coping and anxiety adaptation
- Positive inotropic cardiac effect via CRF-R2 on cardiomyocytes — studied in heart failure research
- Cardioprotective in ischemia-reperfusion injury models via CRF-R2-dependent PKC activation
- Urocortin is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Activates CRF-R2 receptors more potently than CRF (CRH) itself — mediates stress-coping and anxiety adaptation
- Positive inotropic cardiac effect via CRF-R2 on cardiomyocytes — studied in heart failure research
- Cardioprotective in ischemia-reperfusion injury models via CRF-R2-dependent PKC activation
- Reduces food intake via hypothalamic CRF-R2 activation — appetite suppression independent of CRF-R1
In Plain English
Simple summaryUrocortin is a neuropeptide discovered in 1995 as a close structural relative of CRF (corticotropin-releasing factor) -- the hypothalamic hormone that drives the stress response by telling the pituitary to release ACTH. Urocortin activates CRF receptors (particularly CRFR2, while CRF itself prefers CRFR1) and has a paradoxical stress-buffering effect: it suppresses appetite, reduces anxiety-like behavior in stress models, and has potent cardioprotective effects during ischemia. Two related peptides (Urocortin 2 and Urocortin 3, which are even more CRFR2-selective) extend the family. Urocortin's cardiac effects are among the most interesting: it reduces the damage from myocardial ischemia-reperfusion injury and has been studied in heart failure, where it improves cardiac output.
- Activates CRF-R2 receptors more potently than CRF (CRH) itself — mediates stress-coping and anxiety adaptation
- Positive inotropic cardiac effect via CRF-R2 on cardiomyocytes — studied in heart failure research
- Cardioprotective in ischemia-reperfusion injury models via CRF-R2-dependent PKC activation
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Urocortin?
Tap any underlined term for an instant definition.
Urocortin is a 40-amino acid peptide that is the mammalian homologue of urotensin I (a fish CRF-like peptide) and a member of the corticotropin-releasing factor (CRF/CRH) peptide family. It was discovered in 1995 by Vaughan et al. in rat brain (Edinger nucleus) and is now known to be expressed in the hypothalamus, brainstem, heart, gut, skin, and reproductive tissues.
The CRF peptide family includes: CRF (41 aa), Urocortin (Ucn1, 40 aa), Urocortin 2 (Ucn2, 38 aa), and Urocortin 3 (Ucn3, 38 aa). They act through two G-protein-coupled receptors: - **CRF-R1**: Higher affinity for CRF and Ucn1; primarily mediates anxiety, HPA axis activation, and stress responses - **CRF-R2**: Higher affinity for Ucn2 and Ucn3; mediates stress adaptation, appetite suppression, and cardiac effects
**Receptor selectivity and functional distinction:** - CRF-R1 activation: Anxiogenic, HPA axis stimulation (ACTH→cortisol), suppresses appetite acutely - CRF-R2 activation: Anxiolytic (opposing CRF-R1), positive cardiac inotropy, sustained appetite suppression, stress coping
Urocortin (Ucn1) activates BOTH receptors and thus has complex, sometimes opposing effects depending on which receptor predominates in a given tissue.
**Cardiac research:** Urocortin's most therapeutically promising application is cardiac function. CRF-R2 is expressed on ventricular cardiomyocytes, and Ucn1/2/3 produce positive inotropic effects, increased coronary blood flow, and cardioprotection against ischemia-reperfusion injury via PKC-ε and MAPK. Phase II trials of Ucn2 (Corticotropin-releasing factor type-2 agonist) in heart failure have been conducted and show improved cardiac output.
**Appetite research:** CRF-R2-mediated appetite suppression complements CRF-R1-mediated effects. Ucn3 (CRF-R2 selective) reduces food intake more durably than CRF-R1 agonism without the anxiety component, making it a research target for obesity.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Urocortin. See all Immune System peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Urocortin is primarily used as a research tool for CRF-R1/R2 pharmacology:
IV injection (anesthetized rat cardiac studies): 10-300 pmol/kg for hemodynamic effects ICV (intracerebroventricular) injection (rodent behavioral studies): 0.1-1 nmol for anxiety/appetite studies Human Phase II heart failure trials (Urocortin 2): 0.1-1 mcg/kg IV bolus followed by infusion
For selective research: Urocortin 2 (preferential CRF-R2) and Urocortin 3 (CRF-R2 selective) are preferred for isolating CRF-R2-mediated effects
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
IV or ICV injection for acute research studies. Requires fresh preparation due to moderate plasma lability. Use 0.1% BSA in PBS as diluent to prevent adsorption.
What the research doesn't show
Most urocortin research is preclinical. Phase 2 trials in acute decompensated heart failure showed improvements in cardiac output and symptoms, but the compounds haven't advanced to Phase 3. The connection between a stress-response neuropeptide and cardiac protection is somewhat counterintuitive, which has made the clinical development pathway more complicated to communicate to both scientific and regulatory audiences.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Urocortin, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Urocortin has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: activates crf-r2 receptors more potently than crf (crh) itself — mediates stress-coping and anxiety adaptation.
The most commonly reported side effect in research subjects is anxiogenic at crf-r1-mediated doses. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
CRF itself strongly activates CRFR1 and drives the classical stress response -- anxiety, HPA axis activation. Urocortin's preference for CRFR2 produces quite different (often opposite) behavioral effects. SS-31 and MOTS-c also have cardiac protective effects but through mitochondrial mechanisms rather than CRF receptor signaling. Among cardiac peptides, urocortin has some of the most compelling ischemia-reperfusion data.
Compare Urocortin side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.